The rationale for targeting the LOX family in cancer - PubMed (original) (raw)

Review

. 2012 Jul 19;12(8):540-52.

doi: 10.1038/nrc3319.

Affiliations

Review

The rationale for targeting the LOX family in cancer

Holly E Barker et al. Nat Rev Cancer. 2012.

Abstract

The therapeutic targeting of extracellular proteins is becoming hugely attractive in light of evidence implicating the tumour microenvironment as pivotal in all aspects of tumour initiation and progression. Members of the lysyl oxidase (LOX) family of proteins are secreted by tumours and are the subject of much effort to understand their roles in cancer. In this Review we discuss the roles of members of this family in the remodelling of the tumour microenvironment and their paradoxical roles in tumorigenesis and metastasis. We also discuss how targeting this family of proteins might lead to a new avenue of cancer therapeutics.

Trial registration: ClinicalTrials.gov NCT01323933.

PubMed Disclaimer

Similar articles

Cited by

References

    1. J Cell Biochem. 2003 Mar 1;88(4):660-72 - PubMed
    1. Cytokine. 2011 Jul;55(1):90-7 - PubMed
    1. Science. 2005 Nov 18;310(5751):1139-43 - PubMed
    1. Invest Ophthalmol Vis Sci. 2008 Apr;49(4):1459-63 - PubMed
    1. Cancer Res. 2005 Dec 15;65(24):11429-36 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources